The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...

Morgan Stanley and Goldman Sachs issued bullish notes on BioAge (BIOA) based on its obesity drug candidate azelaprag and ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...

President Biden and Sen. Bernie Sanders (I-Vt.) will travel to New Hampshire on Tuesday to speak on health care savings ...

WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing more benefits of these powerful medicines, it’s no wonder appetite ...